Antibiotics for Klebsiella Liver Abscess Study
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01723150|
Recruitment Status : Completed
First Posted : November 7, 2012
Last Update Posted : August 27, 2018
Background: Klebsiella pneumoniae liver abscess is the most common etiology of liver abscess in Singapore and much of Asia, and its incidence is increasing. Current management includes prolonged intravenous antibiotic therapy, but there is limited evidence to guide oral conversion. The implicated K1/K2 capsule strain of Klebsiella pneumoniae is almost universally susceptible to ciprofloxacin, an antibiotic with high oral bioavailability. Our primary aim is to compare the efficacy of early (<1 week) step-down to oral antibiotics, to continuing 4 weeks of intravenous antibiotics, in patients with Klebsiella liver abscess.
Methods/Design: The study is designed as a multi-centre randomised open-label active comparator-controlled non-inferiority trial, with a non-inferiority margin of 12%. Eligible participants will be inpatients over the age of 21 with a CT or ultrasound scan suggestive of a liver abscess, and Klebsiella pneumoniae isolated from abscess fluid or blood. Randomisation into intervention or active control arms will be performed with a 1:1 allocation ratio. Participants randomised to the active control arm will receive IV ceftriaxone 2 grams daily to complete a total of 4 weeks of IV antibiotics. Participants randomised to the intervention arm will be immediately converted to oral ciprofloxacin 750mg twice daily. At week 4, all participants will have abdominal imaging and be assessed for clinical response (CRP <20 mg/l, absence of fever, plus scan showing that the maximal diameter of the abscess has reduced). If criteria are met, antibiotics are stopped; if not, oral antibiotics are continued, with reassessment for clinical response fortnightly. If criteria for clinical response are met by week 12, the primary endpoint of clinical cure is met. A cost analysis will be performed to assess the cost saving of early conversion to oral antibiotics, and a quality-of-life analysis will be performed to assess if treatment with oral antibiotics is less burdensome than prolonged IV antibiotics.
Discussion: Our results would help inform local and international practice guidelines regarding the optimal antibiotic management of Klebsiella liver abscess. A finding of non-inferiority may translate to the wider adoption of a more cost-effective strategy that reduces hospital length of stay and improves patient-centered outcomes and satisfaction.
|Condition or disease||Intervention/treatment||Phase|
|Liver Abscess, Pyogenic||Drug: Ciprofloxacin Drug: Ceftriaxone Drug: Trimethoprim/sulfamethoxazole Drug: Ertapenem||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||152 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Multi-centre Randomised Open-label Active Comparator-controlled Non-inferiority Trial Comparing Oral to Intravenous Antibiotics in the Early Management of Klebsiella Pneumoniae Liver Abscess|
|Actual Study Start Date :||November 5, 2013|
|Actual Primary Completion Date :||January 16, 2018|
|Actual Study Completion Date :||January 16, 2018|
Experimental: Oral antibiotics
The intervention arm switched to oral antibiotics to complete 4 weeks of therapy. Oral antibiotics will be ciprofloxacin (or trimethoprim/sulfamethoxazole if the isolate is resistant).
Other Name: Bactrim
Active Comparator: Intravenous antibiotics
The active comparator arm continues intravenous antibiotics to complete 4 weeks of therapy. Intravenous antibiotics will be ceftriaxone (or ertapenem if the isolate is resistant).
- Clinical cure [ Time Frame: Week 12 ]The primary endpoint is "clinical cure", determined at Week 12 post-randomisation, and defined as CRP< 20 mg/l, plus absence of documented fever ≥38°C in the preceding week, plus most recent abdominal imaging showing that the maximal diameter of the abscess has reduced.
- Clinical response [ Time Frame: Week 4 ]The main secondary endpoint is "clinical response", determined at Week 4 post-randomisation, and defined as CRP <20 mg/l, plus absence of documented fever ≥38°C in the preceding week, plus most recent abdominal imaging showing that the maximal diameter of the abscess has reduced.
- all-cause mortality at any point between randomisation and week 12 [ Time Frame: Week 12 ]
- • unplanned readmission for any cause at any point between hospital discharge and week 12 [ Time Frame: Week 12 ]
- • unplanned need for drainage after enrolment at any point between randomisation and week 12 (the screening visit will document any plans for elective drainage) [ Time Frame: Week 12 ]
- • metastatic complications occurring at any point between randomisation and week 12 [ Time Frame: Week 12 ]
- new K. pneumoniae bacteraemia occurring at any point between the first negative blood culture, and week 12, with the same strain of K. pneumoniae as the original blood culture or abscess fluid culture [ Time Frame: Week 12 ]
- • length of hospital stay (from the date of randomisation to the end of inpatient stay, censored at week 12) [ Time Frame: Week 12 ]
- • length of time the subject requires medical leave following hospital discharge (censored at week 12) [ Time Frame: Week 12 ]
- • subject quality of life as defined by the WHOQOL-BREF assessed at week 4 and week 12 post-randomisation [ Time Frame: Week 12 ]
- • overall cost of each treatment strategy from the payer and total societal perspective for the course of the study until the final twelve week follow-up [ Time Frame: Week 12 ]
- • level of adherence during the entire study period, assessed at twelve weeks. Subject deemed to be compliant if 80% or more of prescribed antibiotics have been taken [ Time Frame: Week 12 ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01723150
|Singapore General Hospital|
|Singapore, Singapore, 169856|
|National University Hospital|
|Tan Tock Seng Hospital|
|Principal Investigator:||Sophia Archuleta, MD||National University Hospital, Singapore|